Dr. Mandeep Singh Saluja, MD

Dr. Saluja practices at St Luke's Hospital Quakertown Campus - Outpatient Respiratory Pft Lab - HOPD in Quakertown, Pennsylvania.

Dr. Saluja's NPI, 1801022108, was assigned on June 2, 2009. Dr. Saluja holds New York license 250569.

Dr. Saluja's primary practice is St Luke's Hospital Quakertown Campus - Outpatient Respiratory Pft Lab - HOPD, at 1021 Park Ave, Quakertown, PA 18951.

Dr. Saluja's primary practice is St Luke's Hospital Quakertown Campus - Outpatient Respiratory Pft Lab - HOPD in Quakertown, Pennsylvania. Dr. Saluja is also affiliated with St. Luke's Hospital - Upper Bucks Campus. The medical group on file is St. Luke's South Mountain Family Practice. Dmand AI also links Dr. Saluja to 3 more hospitals, 1 dialysis center, 1 home health agency and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Saluja practices, 7 sites in all. Vendor and product names are available with a free account.

Internal medicine is Dr. Saluja's primary specialty in the NPI Registry, under taxonomy code 207R00000X. Dr. Saluja is licensed in New York.

CMS data shows 1,023 Medicare services from Dr. Saluja across 5 procedure codes in 2024, for 405 Medicare patients. Medicare paid $85,332 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 405 Medicare patients who saw Dr. Saluja in 2024. The largest group is 65 to 74, with 141 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 25% are also on Medicaid. Their average risk score is 2.56, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Saluja's median patient age at 76, with 51% women.

In 2024, Dr. Saluja wrote 260 Medicare Part D claims for 146 patients. 91% of them were for generic drugs. CMS names the drug for 45 of them, across 3 drugs with 11 or more claims each, at $320 in total drug cost. In 2023, CMS named 95 claims across 7 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 97 out of 100 for Dr. Saluja for performance year 2024, reported through an alternative payment model (APM). Dr. Saluja accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

CMS Open Payments shows 7 general payments to Dr. Saluja from 1 drug or device company from 2023 to 2024. Food and beverage make up the largest share, 100% of the total. Janssen Pharmaceuticals, Inc paid the most, $243.